5th Qatar BIM User Day, Expanding BIM into Augmented and Virtual Reality
VIRTUAL CONFERENCE THE 5th 4GIANT STEPS …
1
AGENDA 4 GIANT STEPS IN DYSLIPIDEMIA | HEART FAILURE KIDNEY PROTECTION | DIABETES THE 5 th ANNUAL CARDIOMETABOLIC DISEASE 9:00 am Opening remarks Dr. Ronald Goldenberg 9:05 am The 2020 Canadian Lipid Guidelines: What’s new and important? Dr. George Thanassoulis 9:20 am From REDUCE-IT to EVAPORATE: IPE comes of age Dr. Subodh Verma 9:35 am Targeting PCSK9 with monoclonal antibodies and small interfering RNAs Dr. Lawrence Leiter 9:50 am Panel discussion 10:05 am DAPA-HF and EMPEROR-Reduced: Two trials, one story Dr. Subodh Verma 10:20 am When and where should we use ARNIs? Dr. Shelley Zieroth 10:35 am Panel discussion 10:50 am CREDENCE, DAPA-CKD AND FIDELIO- DKD: Protecting the kidneys Dr. David Cherney 11:05 am GLP-1RAs for diabetes: A recap of 2020 Dr. Irene Hramiak 11:20 am GLP-1RAs + SGLT2i combination therapy Dr. Ronald Goldenberg 11:35 am Panel discussion 11:50 am Closing remarks Dr. Subodh Verma SATURDAY, DECEMBER 19, 2020 9:00 AM - 11:50 AM EST Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA, FACC Endocrinologist, St. Michael’s Hospital; Professor of Medicine and Nutritional Sciences, University of Toronto, Toronto, ON, Canada Subodh Verma, MD, PhD, FRCSC, FAHA CO-CHAIR Cardiac Surgeon, St. Michael’s Hospital; Professor of Surgery and Pharmacology & Toxicology, University of Toronto; Canada Research Chair in Cardiovascular Surgery, Toronto, ON, Canada David Z. I. Cherney, MD CM, PhD, FRCPC Nephrologist, University Health Network and Mount Sinai Hospital Professor of Medicine, University of Toronto, Toronto, ON, Canada Ronald M. Goldenberg, MD, FRCPC, FACE CO-CHAIR Consultant Endocrinologist, LMC Diabetes & Endocrinology Vaughan, ON, Canada FACULTY George Thanassoulis, MD, MSc, FRCPC Cardiologist and Director of Preventive and Genomic Cardiology, McGill University Health Centre; Associate Professor of Medicine, McGill University, Montréal, QC, Canada Irene M. Hramiak, MD, FRCP(C), MACP Endocrinologist and Site Chief of Medicine, St. Joseph’s Health Care; Professor of Medicine, Western University, London, ON, Canada REGISTER AT: www.4GiantSteps.com LEARNING OBJECTIVES Shelley Zieroth, MD, FRCPC, FCCS, FHFSA, FESC, FACC Cardiologist and Director, St. Boniface Hospital Heart Failure and Transplant Clinics; Head, Medical Heart Failure Program, WRHA Cardiac Sciences Program; Associate Professor of Medicine, University of Manitoba; President, Canadian Heart Failure Society; Winnipeg, MB, Canada For more information about this program please contact S&L Solutions at 647-462-1138 or [email protected] This program has been supported by educational grants from: Bayer, Boehringer Ingelheim and Eli Lilly and Company Alliance, Janssen, HLS Therapeutics, and Novo Nordisk VIRTUAL CONFERENCE At the conclusion of this program the Learner will be able to: • Describe the recently updated guidelines and trial data on dyslipidemia management • Apply current dyslipidemia guideline recommendations for primary and secondary cardiovascular risk prevention • Explain the different types of heart failure and their pathophysiologies • Discriminate between the available heart failure therapies based on patient characteristics and drug safety/efficacy • Summarize the findings from contemporary kidney outcome trials and how they may impact on clinical care • Describe the data from recently reported GLP-1RA trials • Discuss the current guideline recommendations for selecting GLP-1RAs and SGLT2 inhibitors
Transcript of VIRTUAL CONFERENCE THE 5th 4GIANT STEPS …
AGENDA
4GIANT STEPS IN
DYSLIPIDEMIA | HEART FAILURE KIDNEY PROTECTION | DIABETES
THE 5th ANNUAL
CARDIOMETABOLIC DISEASE
9:00 am Opening remarks Dr. Ronald Goldenberg
9:05 am The 2020 Canadian Lipid Guidelines: What’s new and important?
Dr. George Thanassoulis
9:20 am From REDUCE-IT to EVAPORATE: IPE comes of age
Dr. Subodh Verma
9:35 am Targeting PCSK9 with monoclonal antibodies and small interfering RNAs
Dr. Lawrence Leiter
9:50 am Panel discussion10:05 am DAPA-HF and EMPEROR-Reduced:
Two trials, one storyDr. Subodh Verma
10:20 am When and where should we use ARNIs?
Dr. Shelley Zieroth
10:35 am Panel discussion10:50 am CREDENCE, DAPA-CKD AND FIDELIO-
DKD: Protecting the kidneysDr. David Cherney
11:05 am GLP-1RAs for diabetes: A recap of 2020
Dr. Irene Hramiak
11:20 am GLP-1RAs + SGLT2i combination therapy
Dr. Ronald Goldenberg
11:35 am Panel discussion11:50 am Closing remarks Dr. Subodh Verma
SATURDAY, DECEMBER 19, 2020 9:00 AM - 11:50 AM EST
Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA, FACCEndocrinologist, St. Michael’s Hospital; Professor of Medicine and NutritionalSciences, University of Toronto,Toronto, ON, Canada
Subodh Verma, MD, PhD, FRCSC, FAHACO-CHAIRCardiac Surgeon, St. Michael’s Hospital; Professor of Surgery and Pharmacology & Toxicology, University of Toronto; Canada Research Chair in Cardiovascular Surgery, Toronto, ON, Canada
David Z. I. Cherney, MD CM, PhD, FRCPCNephrologist, University Health Network and Mount Sinai HospitalProfessor of Medicine, University of Toronto,Toronto, ON, Canada
Ronald M. Goldenberg, MD, FRCPC, FACECO-CHAIRConsultant Endocrinologist,LMC Diabetes & Endocrinology Vaughan, ON, Canada
FACULTY
George Thanassoulis,MD, MSc, FRCPCCardiologist and Director of Preventive and Genomic Cardiology, McGill University Health Centre;Associate Professor of Medicine, McGill University, Montréal, QC, Canada
Irene M. Hramiak, MD, FRCP(C), MACPEndocrinologist and Site Chief of Medicine, St. Joseph’s Health Care;Professor of Medicine, Western University, London, ON, Canada
REGISTER AT: www.4GiantSteps.com
LEARNING OBJECTIVES
Shelley Zieroth, MD, FRCPC, FCCS, FHFSA, FESC, FACCCardiologist and Director, St. Boniface Hospital Heart Failure and Transplant Clinics; Head, Medical Heart Failure Program, WRHA Cardiac Sciences Program; Associate Professor of Medicine, University of Manitoba; President, Canadian Heart Failure Society; Winnipeg, MB, Canada
For more information about this program please contact S&L Solutions at 647-462-1138 or [email protected] program has been supported by educational grants from:
Bayer, Boehringer Ingelheim and Eli Lilly and Company Alliance, Janssen, HLS Therapeutics, and Novo Nordisk
VIRTUAL CONFERENCE
At the conclusion of this program the Learner will be able to:• Describe the recently updated guidelines and trial data on dyslipidemia management• Apply current dyslipidemia guideline recommendations for primary and secondary cardiovascular risk prevention • Explain the different types of heart failure and their pathophysiologies• Discriminate between the available heart failure therapies based on patient characteristics and drug safety/efficacy • Summarize the findings from contemporary kidney outcome trials and how they may impact on clinical care• Describe the data from recently reported GLP-1RA trials• Discuss the current guideline recommendations for selecting GLP-1RAs and SGLT2 inhibitors
